C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation PortfolioGlobeNewsWire • 01/10/22
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 11/22/21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/10/21
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/11/21
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple MyelomaGlobeNewsWire • 08/11/21
C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/21/21
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic MalignanciesGlobeNewsWire • 06/14/21
C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein DegradationGlobeNewsWire • 06/07/21
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial ResultsGlobeNewsWire • 05/13/21
C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021GlobeNewsWire • 04/10/21
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial ResultsGlobeNewsWire • 03/11/21
C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/10/21
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic MalignanciesGlobeNewsWire • 01/19/21